Fampyra (fampridine) vs Ponvory (ponesimod)
Fampyra (fampridine) vs Ponvory (ponesimod)
Fampyra (fampridine) is a potassium channel blocker designed to improve walking in patients with multiple sclerosis (MS) by increasing nerve signal conduction. Ponvory (ponesimod) is a selective sphingosine-1-phosphate receptor modulator used to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, by reducing the immune system's attack on the nervous system. When deciding between the two, a patient should consider their specific type of MS, their symptoms (e.g., walking difficulties for Fampyra and overall relapse reduction for Ponvory), and consult with their healthcare provider to determine the most appropriate treatment based on their individual health profile and treatment goals.
Difference between Fampyra and Ponvory
| Metric | Fampyra (fampridine) | Ponvory (ponesimod) |
|---|---|---|
| Generic name | Fampridine | Ponesimod |
| Indications | Improvement of walking in patients with multiple sclerosis (MS) | Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease |
| Mechanism of action | Potassium channel blocker | S1P receptor modulator |
| Brand names | Fampyra | Ponvory |
| Administrative route | Oral | Oral |
| Side effects | Urinary tract infection, insomnia, dizziness, headache, nausea, weakness, back pain | Upper respiratory infection, elevated liver enzymes, high blood pressure, breathing problems |
| Contraindications | History of seizures, moderate to severe renal impairment | Patients with CYP2C9*3/*3 genotype, recent (within the last 6 months) heart attack, stroke or certain types of heart failure, severe untreated sleep apnea |
| Drug class | Potassium channel blocker | Sphingosine 1-phosphate receptor modulator |
| Manufacturer | Biogen | Janssen Pharmaceuticals |
Efficacy
Fampyra (Fampridine) Efficacy in Multiple Sclerosis
Fampyra, known generically as fampridine, is a medication approved for use in improving walking in adults with Multiple Sclerosis (MS). This potassium channel blocker is specifically indicated to enhance walking speed in MS patients who have demonstrated walking disability. Clinical trials have shown that fampridine can increase walking speed in some individuals with MS. The efficacy of Fampyra was demonstrated in several clinical trials, including a study where a significantly greater proportion of patients on fampridine had a consistent improvement in their walking speed compared to those on placebo.
However, it is important to note that Fampyra does not work for everyone with MS, and its efficacy can vary from person to person. The drug's effectiveness is often assessed through a walking test over a short duration, and continued use is typically dependent on demonstrating a measurable improvement in walking ability. Fampyra is not a cure for MS, but rather a symptomatic treatment to improve a specific function that can be compromised by the disease.
Ponvory (Ponesimod) Efficacy in Multiple Sclerosis
Ponvory, or ponesimod, is a selective sphingosine-1-phosphate receptor modulator approved for the treatment of adults with relapsing forms of Multiple Sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponesimod works by trapping certain white blood cells in lymph nodes, preventing them from reaching the central nervous system where they could cause inflammation and damage that is characteristic of MS.
The efficacy of Ponvory was established in a clinical trial comparing it to another MS medication, teriflunomide, in patients with relapsing forms of MS. The study showed that Ponvory significantly reduced the annual relapse rate over a period of time compared to teriflunomide. Additionally, Ponvory demonstrated a reduction in the number of new or enlarging brain lesions observed on MRI scans. These results suggest that Ponvory can effectively reduce the clinical and radiological activity of the disease in patients with relapsing MS.
Regulatory Agency Approvals
Fampyra
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Ponvory
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Fampyra or Ponvory today
If Fampyra or Ponvory are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us